Shots:

• The EMA’s CHMP has recommended the use of casirivimab + imdevimab in patients with confirmed COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19
• The CHMP scientific opinion supports national decision making within EU states on the use of the antibodies- prior to the future EMA market authorization
• Regeneron collaborated with Roche to increase the global supply of the antibody cocktail. Regeneron is responsible for the development and distribution of the treatment in the US and Roche is primarily responsible outside the US and has already begun distribution in the EU

 ­ Ref: Regeneron | Image: Foursquare